Related Experiment Video
Updated: Feb 10, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
Clinical trials for precision oncology using next-generation sequencing
1Biometric Research Branch, National Cancer Institute, 9609 Medical Center Drive, Room 5W110, MSC 9735, Bethesda, MD 20892, USA. rsimon@nih.gov .
Abstract:
The demonstrated genomic heterogeneity of human cancers is having major impacts on the development and evaluation of cancer therapeutics and molecular diagnostics. Many new cancer drugs target somatic alterations in tumors and are being developed with companion diagnostics. Oncology drug development and practice are likely to become increasingly stratified and utilize the enrichment Phase III trial paradigm. Although this paradigm includes an increasing number of successes, single-agent molecularly targeted treatment of metastatic disease will generally provide limited patient benefit. More substantial gains will require better understanding of crosstalk among signaling pathways, ability to combine drugs and use of drugs at initial diagnosis. Early phase discovery clinical trials in which patients will have genome-wide tumor characterization at diagnosis and at critical retreatment points will provide data sets for learning how to effectively match therapeutics to genomic alterations. However, moving tumor genomics to clinical oncology entails many practical challenges. We review some of these challenges and the clinical studies that are being undertaken to translate genomics to clinical oncology.
Insights
Genomic heterogeneity in cancer impacts drug development. Understanding tumor genomics and pathway crosstalk is crucial for effective cancer therapeutics and personalized diagnostics.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Human cancers exhibit significant genomic heterogeneity, influencing therapeutic development and diagnostic strategies.
- Targeted cancer therapies and companion diagnostics are increasingly focused on specific tumor genetic alterations.
- The oncology landscape is shifting towards stratified approaches, including enrichment Phase III trials.
Purpose of the Study:
- To review the challenges and ongoing clinical studies in translating tumor genomics into clinical oncology practice.
- To highlight the need for a deeper understanding of signaling pathway crosstalk for improved cancer treatment outcomes.
- To emphasize the potential of early-phase clinical trials with comprehensive genomic characterization for treatment matching.
Main Methods:
- Review of current challenges in clinical genomics implementation.
- Analysis of clinical studies focused on translating genomic data into oncology.
- Discussion of strategies for effective therapeutic matching based on genomic alterations.
Main Results:
- Single-agent targeted therapies for metastatic disease offer limited patient benefit.
- Substantial gains necessitate understanding pathway crosstalk, drug combinations, and early-stage treatment.
- Early-phase trials with genome-wide tumor characterization are vital for generating data on therapeutic matching.
Conclusions:
- Translating tumor genomics into clinical oncology faces practical hurdles.
- Effective cancer treatment requires a move beyond single-agent therapies to combination strategies informed by comprehensive genomic data.
- Ongoing clinical studies aim to overcome these challenges and integrate genomics into routine cancer care.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Statistical Software for Data Analysis and Clinical Trials
Uncertainty in Measurement: Accuracy and Precision
Trial and Error and Algorithm

